Trending NewsTrending NewsNASDAQ:GOSS Gossamer Bio (GOSS) Stock Price, News & Analysis $0.16 -0.01 (-3.15%) Closing price 06/26/2026 03:59 PM EasternExtended Trading$0.16 +0.00 (+1.25%) As of 06/26/2026 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock About Gossamer Bio Stock (NASDAQ:GOSS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Gossamer Bio alerts:Sign Up Key Stats Today's Range$0.15▼$0.1750-Day Range$0.16▼$0.4552-Week Range$0.14▼$3.87Volume38.29 million shsAverage Volume15.08 million shsMarket Capitalization$37.55 millionP/E RatioN/ADividend YieldN/APrice Target$4.50Consensus RatingHold Company Overview Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need. The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies. In addition to these clinical-stage assets, Gossamer Bio maintains several earlier-stage programs targeting pathways such as integrin and TGF-β signaling. The company’s R&D efforts are supported by a combination of in-house research capabilities and external collaborations with academic centers and contract research organizations. Gossamer Bio completed its initial public offering in July 2019 and has since advanced multiple clinical trials across North America and selected international sites. The company is led by President and Chief Executive Officer Thomas A. Whiting, a veteran of the biopharmaceutical industry with over 25 years of drug development experience. Under his leadership, Gossamer Bio continues to build a multidisciplinary management team focused on accelerating the translation of scientific insights into therapeutic candidates.AI Generated. May Contain Errors. Read More Gossamer Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreGOSS MarketRank™: Gossamer Bio scored higher than 57% of companies evaluated by MarketBeat, and ranked 416th out of 852 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingHold Consensus RatingGossamer Bio has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on no strong buy ratings, 4 buy ratings, 4 hold ratings, and 2 sell ratings.Upside PotentialGossamer Bio has a consensus price target of $4.50, representing about 2,712.5% upside from its current price of $0.16.Amount of Analyst CoverageGossamer Bio has only been the subject of 2 research reports in the past 90 days.Read more about Gossamer Bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Gossamer Bio are expected to grow in the coming year, from ($0.45) to ($0.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Gossamer Bio is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Gossamer Bio is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Gossamer Bio's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted24.88% of the float of Gossamer Bio has been sold short.Short Interest Ratio / Days to CoverGossamer Bio has a short interest ratio ("days to cover") of 3.41, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Gossamer Bio has recently decreased by 10.51%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGossamer Bio does not currently pay a dividend.Dividend GrowthGossamer Bio does not have a long track record of dividend growth. News and Social Media1.9 / 5News Sentiment-0.03 News SentimentGossamer Bio has a news sentiment score of -0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Gossamer Bio this week, compared to 8 articles on an average week.Search InterestOnly 2 people have searched for GOSS on MarketBeat in the last 30 days. This is a decrease of -82% compared to the previous 30 days.MarketBeat Follows5 people have added Gossamer Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Gossamer Bio insiders have not sold or bought any company stock.Percentage Held by Insiders3.74% of the stock of Gossamer Bio is held by insiders.Percentage Held by Institutions81.23% of the stock of Gossamer Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Gossamer Bio's insider trading history. Receive GOSS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gossamer Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GOSS Stock News HeadlinesGossamer Bio Announces $120 Million Private Placement FinancingJune 25 at 8:42 AM | businesswire.comGossamer Bio (GOSS) Stock Faces Mixed Analyst Target Changes On Funding RiskJune 18, 2026 | finance.yahoo.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.June 27 at 1:00 AM | Profits Run (Ad)Gossamer Bio Inc (GOSS) Q1 2026 Earnings Call Highlights: Strategic Debt Reduction and ...June 17, 2026 | finance.yahoo.comGossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible NotesJune 17, 2026 | finance.yahoo.comGossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible NotesJune 4, 2026 | finance.yahoo.comGossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible NotesJune 3, 2026 | businesswire.comGossamer Bio, Inc. Announces Extension of Early Tender Date for Exchange Offer and Consent Solicitation with Respect to Existing Convertible NotesJune 2, 2026 | finance.yahoo.comSee More Headlines GOSS Stock Analysis - Frequently Asked Questions How have GOSS shares performed this year? Gossamer Bio's stock was trading at $3.10 at the beginning of the year. Since then, GOSS stock has decreased by 94.8% and is now trading at $0.16. How were Gossamer Bio's earnings last quarter? Gossamer Bio, Inc. (NASDAQ:GOSS) released its earnings results on Friday, May, 15th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.17) by $0.03. The business had revenue of $16.96 million for the quarter, compared to analyst estimates of $4.67 million. Read the conference call transcript. When did Gossamer Bio IPO? Gossamer Bio (GOSS) raised $230 million in an initial public offering on Friday, February 8th 2019. The company issued 14,400,000 shares at $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI acted as the underwriters for the IPO. Who are Gossamer Bio's major shareholders? Gossamer Bio's top institutional shareholders include Kalehua Capital Management LLC (4.36%), Octagon Capital Advisors LP (3.30%), Bank of America Corp DE (1.35%) and Rock Springs Capital Management LP (0.69%). Insiders that own company stock include Faheem Hasnain, Richard Aranda and Bryan Giraudo. View institutional ownership trends. How do I buy shares of Gossamer Bio? Shares of GOSS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Gossamer Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Gossamer Bio investors own include Voyager Therapeutics (VYGR), Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), The RMR Group (RMR), AUO (AUOTY) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings5/15/2026Today6/27/2026Next Earnings (Estimated)8/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 GOSS's financial health is in the Red zone, according to TradeSmith. GOSS has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GOSS CIK1728117 Webwww.gossamerbio.com Phone(858) 684-1300FaxN/AEmployees180Year Founded2015Price Target and Rating Average Price Target for Gossamer Bio$4.50 High Price Target$11.00 Low Price Target$1.00 Potential Upside/Downside+2,712.5%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($0.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$170.37 million Net Margins-324.82% Pretax Margin-324.98% Return on EquityN/A Return on Assets-96.10% Debt Debt-to-Equity RatioN/A Current Ratio2.20 Quick Ratio2.20 Sales & Book Value Annual Sales$55.54 million Price / Sales0.68 Cash FlowN/A Price / Cash FlowN/A Book Value($0.53) per share Price / Book-0.30Miscellaneous Outstanding Shares234,696,000Free Float225,918,000Market Cap$37.55 million OptionableOptionable Beta2.00 Social Links 10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:GOSS) was last updated on 6/27/2026 by MarketBeat.com Staff. From Our PartnersTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredSpaceX is offering you shares. Don't take them.SpaceX is reserving 30% of its IPO shares for retail investors through Robinhood, Fidelity, and Schwab. At a $...Behind the Markets | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredElon’s new "tollbooth"The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gossamer Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gossamer Bio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
